Gapping down
In reaction to earnings/guidance:
- PVTL -26.3%, KR -8%, OXM -4.7%, HOLX -1.6% (provides update on the financial impact of recent actions; expects Q4 Cynosure revenue to be approx $15 mln lower than prior guidance but reaffirms overall sales guidance)
Other news:
- PGNX -20.3% (reports top line data for Phase 3 study on a prostate cancer visualization agent; co-primary endpoint of sensitivity was not met)
- ACOR -17.8% (FDA has extended the PDUFA goal date for its review of the INBRIJA NDA from October 5, 2018 to January 5, 2019)
- SRTS -11.5% (commenced public offering of common stock)
- HLNE -4.4% (commences underwritten public offering of 2,880,979 shares of Class A common stock by Hamilton Lane and certain selling stockholders; also filed for 15 mln share Class A common stock shelf offering by selling stockholders )
- FOMX -4.3% (proposed follow-on underwritten public offering of $70 mln of its ordinary shares)
- GBT -3.7% (Stat News' Adam Feuerstein out cautious ahead of expected FDA submission for voxelotor in SCD)
- HL -2.4% (filed for approx 1.87 mln share common stock offering by selling shareholders)
- XENE -1.8% (prices 4.5 mln shares of common stock at $14.00 per share)
- FND -1% (announces secondary offering of 10 mln shares by selling stockholders)
Analyst comments:
- FNSR -4% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- FEDU -3.3% (downgraded to Sell from Neutral at Citigroup)
- CIEN -2.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- W -2.5% (downgraded to Neutral from Buy at BofA/Merrill)
- HOLX -1.6% (downgraded to Neutral from Buy at BofA/Merrill)
- TXRH -1.2% (downgraded to Neutral from Buy at BTIG Research)
![]()